International Flavors & Fragrances Inc.

(New York Stock Exchange)
Back to all articles
Bullish +75

IFF Reports First Quarter 2026 Results

AI-generated analysis

πŸ“ˆ IFF reported consolidated net sales of $2.74 billion for Q1 2026, representing a 4% decrease on a reported basis but a 3% increase on a comparable, currency-neutral basis.

πŸ’° Adjusted operating EBITDA reached $568 million in the quarter, an 8% improvement year-over-year driven by volume growth and productivity gains.

πŸ“Š Reported earnings per share (EPS) was $0.66, while adjusted EPS excluding amortization came in at $1.25 per diluted share.

πŸ’§ Cash flows from operations increased to $257 million, while free cash flow rose significantly to $92 million compared to the prior year.

🏦 The company maintained a healthy balance sheet with a net debt to credit-adjusted EBITDA ratio of 2.5x at the end of the quarter.

πŸ₯« Taste segment sales increased 18% on a comparable basis, contributing $153 million in adjusted operating EBITDA with a 23.3% margin.

πŸ’Š Health Biosciences delivered strong performance with 7% growth in adjusted operating EBITDA, primarily driven by volume increases across businesses.

🧴 Scent segment sales saw a slight decrease of 2% on a comparable basis due to unfavorable pricing on input costs despite volume growth.

🍲 Food Ingredients division achieved a 12% increase in adjusted operating EBITDA, supported by productivity gains and volume growth in key areas.

πŸ’Ό The company reaffirmed its full-year 2026 guidance, expecting total sales between $10.5 billion and $10.8 billion.

🀝 IFF is continuing a disciplined sale process for its Food Ingredients business to maximize shareholder value while operating in an unsettled environment.

βš–οΈ The full-year financial outlook includes two months of results from the divested Soy Crush, Concentrates, and Lecithin businesses following a March 2 closing.

πŸ’Ή Management expects foreign exchange rates to provide approximately a 1% positive impact on overall sales growth during the remainder of 2026.

⚠️ Proceeds from recent divestitures are anticipated to have an approximate 5% adverse impact on both sales and adjusted operating EBITDA for the full year.

πŸ“£ CEO Erik Fyrwald highlighted a solid operational execution and customer focus that helped deliver volume growth across all four business segments.

πŸ—“οΈ A live webcast discussing these Q1 2026 financial results is scheduled to take place on May 6, 2026, at 9:00 a.m. ET.

Bullish Signals
  • IFF delivered solid top and bottom line Q1 2026 results, with CEO Erik Fyrwald noting volume growth in all four segments, improved profitability, and strong cash flow.
  • Comparable currency-neutral sales increased 3% versus the prior year despite a reported decline, demonstrating robust underlying demand across all businesses.
  • Adjusted operating EBITDA improved 8% on a comparable basis, driven by volume growth and productivity gains which helped offset inflationary pressures.
  • The company reaffirmed its full-year 2026 financial guidance of $10.5 billion to $10.8 billion in sales and $2.05 billion to $2.15 billion in adjusted operating EBITDA, signaling confidence despite an unsettled environment.
  • Cash flows from operations surged to $257 million, representing a $130 million increase year-over-year, while free cash flow increased significantly to $92 million.
  • The disciplined sale process for the Food Ingredients business is underway to maximize value for shareholders following the accelerated divestiture closing on March 2, 2026.
  • Health Biosciences segment showed broad-based growth with adjusted operating EBITDA increasing 7% primarily driven by volume growth.
  • Foreign exchange rates are expected to provide an approximately 1% positive impact on sales growth for the full year 2026.
Risk Factors
  • Reported net sales decreased 4% year-over-year to $2.74 billion, indicating a decline in top-line revenue despite volume growth.
  • Adjusted operating EBITDA for the Scent segment decreased by 2% on a comparable basis as unfavorable pricing on input costs outweighed volume and productivity gains.
  • The divestiture of the Soy Crush, Concentrates, and Lecithin business is expected to have an approximately 5% adverse impact on both sales and adjusted operating EBITDA growth for the full year 2026.
  • Reported net income guidance must be reconciled against a total debt-to-trailing-twelve-months-net-income ratio of 7.2x, which is elevated compared to peers.
  • Full-year sales guidance relies on an assumed 1% positive impact from foreign exchange rates, creating dependency on volatile currency markets.
  • The operating environment remains unsettled, necessitating a conservative disciplined approach to planning the balance of the year.
Full Analysis
International Flavors & Fragrances (NYSE: IFF) reported first quarter 2026 results on May 7, 2026, indicating a solid start to the year with strong operational execution despite an unsettled operating environment. CEO Erik Fyrwald highlighted volume growth across all four business segments, improved profitability, and robust cash flow generation for the quarter ended March 31, 2026. The company reaffirmed its full-year 2026 financial guidance, maintaining a disciplined sale process for its Food Ingredients business to maximize shareholder value while working with customers to mitigate inflation impacts. Consolidated financial results for the first quarter showed reported net sales of $2.74 billion, down 4% year-over-year on a reported basis but increasing 3% on a comparable, currency-neutral basis. Adjusted operating EBITDA rose 8% year-over-year on a comparable, currency-neutral basis to $568 million, driven by volume growth and productivity gains. Reported earnings per share were $0.66, while adjusted EPS excluding amortization stood at $1.25 per diluted share. Cash flows from operations increased significantly by $130 million year-over-year to $257 million, with free cash flow reaching $92 million. Segment performance varied across the company's divisions, with Taste generating $656 million in sales and Health Biosciences reporting $595 million in sales, both showing comparable growth. Scent segment sales were $651 million with a slight decrease in adjusted operating EBITDA due to unfavorable input costs offsetting volume gains, while Food Ingredients reported $839 million in sales with strong growth led by volume increases. The divestiture of the Soy Crush, Concentrates, and Lecithin business closed earlier than expected on March 2, 2026, leading to a revised full-year outlook that includes only two months of its results rather than three. IFF maintains full-year 2026 sales guidance between $10.5 billion and $10.8 billion, with adjusted operating EBITDA expected in the range of $2.05 billion to $2.15 billion. The company expects comparable currency-neutral sales growth of 1% to 4% and comparable currency-neutral adjusted operating EBITDA growth of 3% to 8%. Foreign exchange rates are anticipated to provide a 1% positive impact on sales growth but no impact on adjusted operating EBITDA, while divestitures are projected to have an adverse impact of approximately 5% on both metrics. A webcast discussing these results is scheduled for May 6, 2026, at 9:00 a.m. ET.